Under different pathological conditions, high levels of reactive oxygen species (ROS) cause substantial damage to multiple organs. To counter these ROS levels in multiple organs, we have engineered highly potent novel terpolymers. We found that combination of FDA-approved polyethylene glycol, fumaric acid moieties and electroactive tetra(aniline) by varying the content of tetra(aniline) results into a novel drug composition with biologically active tunable intrinsic antioxidant properties. To test tunable intrinsic antioxidative properties of these engineered novel terpolymers, we used alloxan to induce diabetes in rats where ROS generation is known to be higher. The systemic administration of terpolymers to the diabetic rats showed strong electroactive antioxidant behavior which normalized ROS levels, enzymatic antioxidants including superoxide dismutase, catalase, but also reduced glutathione. As a proof-of-principle, we here show TANI based novel drug composition of terpolymers with tunable intrinsic antioxidant effects confirmed in multiple organs.